Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10003740 | 0.93 | SMO (0.45) | SMOSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL10004932 | 0.93 | SMO (0.50) | SMOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10004847 | 0.92 | SMO (0.45) | SMOSMN1; SMN2GABRA2GABRB2MEN1 | |
| SCHEMBL10003808 | 0.91 | GABRA2 (0.40) | SMN1; SMN2HKDC1GABRA2GABRB2MEN1 | |
| SCHEMBL10004059 | 0.90 | SMO (0.46) | SMOSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL10003908 | 0.90 | SMO (0.47) | SMOSMN1; SMN2HKDC1MEN1KMT2A | |
| SCHEMBL10003872 | 0.88 | SMO (0.40) | SMOSMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL10004152 | 0.86 | SMO (0.47) | SMOSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10004293 | 0.86 | GABRA2 (0.39) | SMN1; SMN2HKDC1GABRA2GABRB2MEN1 | |
| SCHEMBL10004269 | 0.85 | SMO (0.40) | SMOSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471790-B1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8907089-B2 | Fused heterocyclic ring derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471790-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220570-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | SMO 1/4885SMN1; SMN2 3164/4885HKDC1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.